Solid Tumor, Lymphoma
Conditions
Keywords
metastatic, radiotherapy, manganese, abscopal response
Brief summary
Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression would be observed at sites distant to an irradiated field because of the radiotherapy-induced anticancer immune responses, so-called abscopal response. Manganese has been confirmed to activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies. This study is designed to assess the abscopal response and safety of combined therapy of manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.
Interventions
Administered by inhalation at 0.4mg/kg/d twice a week
RADIATIONRadiotherapy
Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
Sponsors
Chinese PLA General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects must have histologically proven metastatic solid tumors or lymphoma. 2. Subjects must have at least two distinct measurable sites of disease (≥1 cm). 3. ≥ 18 years old. 4. Life expectancy of at least 6 months. 5. Eastern Cooperative Oncology Group performance status 0-2. 6. Subjects must have stable or progressing disease to the ongoing systemic therapy. 7. Multiple lines of previous chemo-immunotherapy were permitted. 8. Patients with known brain metastases were included in the trial but brain lesions were not eligible as target or non-target lesions. 9. Adequate organ function. 10. Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug. 11. Male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug.
Exclusion criteria
1. Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 2. Serious uncontrolled medical disorders or active infections, pulmonary infection especially. 3. Prior organ allograft. 4. Women who are pregnant or breastfeeding. 5. Women with a positive pregnancy test on enrollment or prior to investigational product administration. 6. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness. 7. Subjects with previous or concurrent other malignancies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects with an abscopal response | 6 months | An abscopal response was defi ned as a decrease in the longest diameter of at least 30% in any measurable (≥1 cm) non-irradiated lesion from baseline. |
| Number of subjects with treatment-related adverse events (AEs) | 12 months | Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | 12 months | DCR is defined as the proportion of subjects who achieved a stable disease (SD), partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
| Progression-free survival (PFS) | 24 months | PFS time was measured from study entry to the first documentation of disease progression or death. Disease progression was determined per the RECIST V1.1. |
| Overall survival (OS) | 24 months | OS time was measured from the study entry to the date of death. |
| Number of participants with laboratory test abnormalities | 12 months | The laboratory tests of serum cytokines and chemokines will be performed on day 1 and 3 of each cycle, and the abnormality will be determined by the investigator. |
Countries
China
Contacts
Primary ContactWeidong Han, M.D.
Outcome results
None listed